BioCryst's oral HAE candidate reduces attack symptom severity in Phase II
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) reported data from 33 evaluable patients treated for a total of 95 acute attacks of hereditary angioedema (HAE) in the Phase II ZENITH-1 trial showing that a single 750 mg dose of oral BCX7353 significantly reduced attack symptom severity as measured by the change from baseline in mean visual analog scale (VAS) score at four hours post dose vs. placebo (reduction of 3.9 points vs. an increase of 3.1 points, p=0.0024).
BCX7353 also significantly reduced the proportion of HAE attacks requiring standard of care (SOC) treatment through 24 hours (29.7% vs. 61.3%, p=0.0029) and increased the proportion of attacks with no or mild symptoms through 24 hours (64.1% vs. 32.3%, p=0.0038) vs. placebo...
BCIQ Company Profiles
BCIQ Target Profiles